The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia

An ENU-induced mouse mutant of SHIP1 reveals a critical role of the stem cell isoform for suppression of macrophage activation

(2011) N.-Y. N. Nguyen et al.   BLOOD

The role of phosphatidylinositol 3-kinase-  in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

(2011) S. E. M. Herman et al.   BLOOD

Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins

(2011) A. Yoshimi et al.   BLOOD

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

(2011) J. Hoellenriegel et al.   BLOOD

Early Relapse in ALL Is Identified by Time to Leukemia in NOD/SCID Mice and Is Characterized by a Gene Signature Involving Survival Pathways

(2011) Lüder Hinrich Meyer et al.   CANCER CELL

Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation

(2011) Zhenya Hong et al.   CARCINOGENESIS

AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias

(2011) Stephen M. Sykes et al.   CELL

Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia

(2011) Simone Boehrer et al.   CELL CYCLE

mTOR complex 2 signaling and functions

(2011) Won Jun Oh et al.   CELL CYCLE

Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors

(2011) J. K. Altman et al.   CLINICAL CANCER RESEARCH

Therapeutic Advances in Acute Myeloid Leukemia

(2011) Alan Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia

(2011) Alejandro Gutierrez et al.   JOURNAL OF EXPERIMENTAL MEDICINE

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance

(2011) Hilmar Quentmeier et al.   Journal of Hematology & Oncology

Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia

(2011) C Evangelisti et al.   LEUKEMIA

A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment

(2011) E Ferretti et al.   LEUKEMIA

PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect

(2011) I Cristóbal et al.   LEUKEMIA

Targeting glycolysis in leukemia: A novel inhibitor 3-BrOP in combination with rapamycin

(2011) Lauren J. Akers et al.   LEUKEMIA RESEARCH

On CK2 regulation of chronic lymphocytic leukemia cell viability

(2011) Leila R. Martins et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Suppression of leukemia development caused by PTEN loss

(2011) W. Guo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species

(2010) M. M. Juntilla et al.   BLOOD

Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia

(2010) L. R. Martins et al.   BLOOD

Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia

(2010) M. Shehata et al.   BLOOD

A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway

(2010) X. Mao et al.   BLOOD

An evolutionarily conserved PTEN-C/EBP -CTNNA1 axis controls myeloid development and transformation

(2010) C.-T. Fu et al.   BLOOD

CAL-101, a p110  selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

(2010) B. J. Lannutti et al.   BLOOD

Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia

(2010) M. Buchner et al.   BLOOD

Phosphatidylinositol 3-kinase-  inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

(2010) S. E. M. Herman et al.   BLOOD

Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E

(2010) Andrew C. Hsieh et al.   CANCER CELL

Modifying Akt Signaling in B-Cell Chronic Lymphocytic Leukemia Cells

(2010) S. W. Hofbauer et al.   CANCER RESEARCH

Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia

(2010) F. Chiarini et al.   CANCER RESEARCH

The role of the PI3K-PKB signaling module in regulation of hematopoiesis

(2010) Miranda Buitenhuis et al.   CELL CYCLE

Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH2 Terminal Kinase Activation and PTEN Upregulation

(2010) J. Redondo-Munoz et al.   CLINICAL CANCER RESEARCH

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

(2010) N. Chapuis et al.   CLINICAL CANCER RESEARCH

Highly Phosphorylated FOXO3A Is an Adverse Prognostic Factor in Acute Myeloid Leukemia

(2010) S. M. Kornblau et al.   CLINICAL CANCER RESEARCH

The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia

(2010) P. Saunders et al.   HAEMATOLOGICA

Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia

(2010) Camilla Evangelisti et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance

(2010) Laura Bonapace et al.   JOURNAL OF CLINICAL INVESTIGATION

Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis

(2010) Ling Gu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Human CD34-Derived Myeloid Dendritic Cell Development Requires Intact Phosphatidylinositol 3-Kinase-Protein Kinase B-Mammalian Target of Rapamycin Signaling

(2010) L. van de Laar et al.   JOURNAL OF IMMUNOLOGY

Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress

(2010) Shomit Sengupta et al.   MOLECULAR CELL

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

(2010) Matthew R Janes et al.   NATURE MEDICINE

The emerging mechanisms of isoform-specific PI3K signalling

(2010) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer

(2010) T Sato et al.   ONCOGENE

Distinct Patterns of DNA Damage Response and Apoptosis Correlate with Jak/Stat and PI3Kinase Response Profiles in Human Acute Myelogenous Leukemia

(2010) David B. Rosen et al.   PLoS One

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

(2010) Nathalie Carayol et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach

(2009) M. Niedermeier et al.   BLOOD

Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia

(2009) R. Crazzolara et al.   BLOOD

Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice

(2009) M. G. Kharas et al.   BLOOD

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia

(2009) A. Gutierrez et al.   BLOOD

Akt1 and Akt2 promote peripheral B-cell maturation and survival

(2009) M. Calamito et al.   BLOOD

Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression

(2009) Wei Ding et al.   BRITISH JOURNAL OF HAEMATOLOGY

Inhibition of Class I Phosphoinositide 3-Kinase Activity Impairs Proliferation and Triggers Apoptosis in Acute Promyelocytic Leukemia without Affecting Atra-Induced Differentiation

(2009) C. Billottet et al.   CANCER RESEARCH

Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia

(2009) F. Chiarini et al.   CANCER RESEARCH

Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy

(2009) L. Fu et al.   CANCER RESEARCH

Chronic myeloid leukemia and BCR/ABL signal pathways are not associated with AKT1 pleckstrin homology domain (E17K) mutations

(2009) Yanli He et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells

(2009) M. de Frias et al.   HAEMATOLOGICA

Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition

(2009) J. Zhuang et al.   HAEMATOLOGICA

Mammalian target of rapamycin activity is required for expansion of CD34+ hematopoietic progenitor cells

(2009) C. R. Geest et al.   HAEMATOLOGICA

Relationship between expression of mutant type glutathione S-transferase theta-1 gene and reactivity of rapamycin in myelodysplastic syndrome

(2009) Yasuhiro Maeda et al.   Hematology

Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-transretinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells

(2009) Chie Nishioka et al.   INTERNATIONAL JOURNAL OF CANCER

Depletion of Pleckstrin Homology Domain Leucine-rich Repeat Protein Phosphatases 1 and 2 by Bcr-Abl Promotes Chronic Myelogenous Leukemia Cell Proliferation through Continuous Phosphorylation of Akt Isoforms

(2009) Isao Hirano et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway

(2009) R Naughton et al.   LEUKEMIA

The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia

(2009) N Gallay et al.   LEUKEMIA

Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia

(2009) P Y Jotta et al.   LEUKEMIA

Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells

(2009) Rami Hayun et al.   LEUKEMIA & LYMPHOMA

Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing

(2009) Tony C.T. Lo et al.   LEUKEMIA RESEARCH

High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics

(2009) Carlos M. Santamaría et al.   LEUKEMIA RESEARCH

mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein

(2009) Manuela Mancini et al.   LEUKEMIA RESEARCH

A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL

(2008) Thomas Decker et al.   ANNALS OF HEMATOLOGY

AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines

(2008) D. S. Levy et al.   BLOOD

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells

(2008) E. Weisberg et al.   BLOOD

FoxO3a regulates hematopoietic homeostasis through a negative feedback pathway in conditions of stress or aging

(2008) K. Miyamoto et al.   BLOOD

mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia

(2008) D. T. Teachey et al.   BLOOD

The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias

(2008) I S Mahmoud et al.   BRITISH JOURNAL OF CANCER

PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation

(2008) Raoul Tibes et al.   BRITISH JOURNAL OF HAEMATOLOGY

Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations

(2008) T. Zenz et al.   BRITISH JOURNAL OF HAEMATOLOGY

Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells

(2008) P. L. Tazzari et al.   CANCER RESEARCH

A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

(2008) D. A. Rizzieri et al.   CLINICAL CANCER RESEARCH

Characteristics of Dasatinib- and Imatinib-Resistant Chronic Myelogenous Leukemia Cells

(2008) S. Okabe et al.   CLINICAL CANCER RESEARCH

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

(2008) Michael G. Kharas et al.   JOURNAL OF CLINICAL INVESTIGATION

PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability

(2008) Ana Silva et al.   JOURNAL OF CLINICAL INVESTIGATION

TSC–mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species

(2008) Chong Chen et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism

(2008) F Chiarini et al.   LEUKEMIA

The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML

(2008) K Kojima et al.   LEUKEMIA

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML

(2008) S Park et al.   LEUKEMIA

Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells

(2008) C Nishioka et al.   LEUKEMIA

Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cellsin vitro, as single agent and in drug combination

(2008) Anna Åleskog et al.   LEUKEMIA & LYMPHOMA

Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor

(2008) Chikara Hirase et al.   LEUKEMIA RESEARCH

The Forkhead Transcription Factor FOXO3a Increases Phosphoinositide-3 Kinase/Akt Activity in Drug-Resistant Leukemic Cells through Induction of PIK3CA Expression

(2008) R. C.-Y. Hui et al.   MOLECULAR AND CELLULAR BIOLOGY

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells

(2008) S Horn et al.   ONCOGENE

SH2-Inositol Phosphatase 1 Negatively Influences Early Megakaryocyte Progenitors

(2008) Lia E. Perez et al.   PLoS One

Inositol trisphosphate 3-kinase B (InsP3KB) as a physiological modulator of myelopoiesis

(2008) Y. Jia et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells

(2007) P. G. Longo et al.   BLOOD